The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk
Abstract
BACKGROUND: Resistant hypertension is a well recognized clinical entity, which has been inadequately researched to date. METHODS: A multivariable Cox model was developed to identify baseline predictors of developing resistant hypertension among 3666 previously untreated Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) patients and construct a risk score to identify those at high risk. Secondary analyses included evaluations among all 19 257 randomized patients. RESULTS: One-third (1258) of previously untreated, and one-half (9333) of all randomized patients (incidence rates 75.2 and 129.7 per 1000 person-years, respectively) developed resistant hypertension during a median follow-up of 5.3 and 4.8 years, respectively. Increasing strata of baseline SBP (151-160, 161-170, 171-180, and >180 mmHg) were associated with increased risk of developing resistant hypertension [hazard ratio 1.24 (95% confidence interval, CI 0.81-1.88), 1.50 (1.03-2.20), 2.15 (1.47-3.16), and 4.43 (3.04-6.45), respectively]. Diabetes, left ventricular hypertrophy, male sex, and raised BMI, fasting glucose, and alcohol intake were other significant determinants of resistant hypertension. Randomization to amlodipine ± perindopril vs. atenolol ± thiazide [0.57 (0.50-0.60)], previous use of aspirin [0.78 (0.62-0.98)], and randomization to atorvastatin vs. placebo [0.87 (0.76-1.00)] significantly reduced the risk of resistant hypertension. Secondary analysis results were similar. The risk score developed allows accurate risk allocation (Harrell's C-statistic 0.71), with excellent calibration (Hosmer-Lemeshow χ statistics, P = 0.99). A 12-fold (8.4-17.4) increased risk among those in the highest vs. lowest risk deciles was apparent. CONCLUSION: Baseline SBP and choice of subsequent antihypertensive therapy were the two most important determinants of resistant hypertension in the ASCOT population. Individuals at high risk of developing resistant hypertension can be easily identified using an integer-based risk score.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The higher prevalence of aTRH among treated hypertensive adults in clinical trials (34%−39%) is likely explained by the selection of patients with demographic and comorbidity characteristics that place them at high risk for the fatal and nonfatal CVD outcomes of interest.21–26”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [22]
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
2007 Guidelines for the Management of Arterial Hypertension
Mancia, G., Backer, G. D., Dominiczak, A. F., Cífková, R., Fagard, R. H., Germanò, G., Grassi, G. M., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,870
Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
Self-citationResistant Hypertension: Diagnosis, Evaluation, and Treatment
Calhoun, D. A., Jones, D. W., Textor, S. C., Goff, D. C., Murphy, T. P., Toto, R. D., White, A. J., Cushman, W. C., White, W. B., Sica, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.189141 · Cited by 2,240
Rothwell, P. M., Howard, S. C., Dolan, E., O'Brien, E., Dobson, J. E., Dahlöf, B., Sever, P. S., & Poulter, N. R. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60308-x · Cited by 1,784
Self-citationThe CAFE Investigators, CAFE Steering Committee and Writing Committee, Williams, B., Lacy, P. S., Thom, S. M., Cruickshank, K., Stanton, A., Collier, D., Hughes, A. D., Thurston, H., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.595496 · Cited by 1,645
Pepine, C. J., Handberg, E. M., Cooper‐DeHoff, R. M., Marks, R. G., Kowey, P. R., Messerli, F. H., Mancia, G., Cangiano, J. L., García-Barreto, D., Keltai, M., et al. (2003) · JAMA · doi:10.1001/jama.290.21.2805 · Cited by 1,278
Applying Cox Regression to Competing Risks
Lunn, M., & McNeil, D. (1995) · Biometrics · doi:10.2307/2532940 · Cited by 1,017
Cited by
Sorted by citations
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
The pathophysiology of hypertension in patients with obesity
DeMarco, V. G., Aroor, A. R., & Sowers, J. R. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.44 · Cited by 545
Beta-blockers for hypertension
Wiysonge, C. S., Bradley, H., Volmink, J. A., Mayosi, B. M., & Opie, L. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002003.pub5 · Cited by 488
Prehypertension—prevalence, health risks, and management strategies
Egan, B. M., & Stevens-Fabry, S. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.17 · Cited by 247
Hypertension in the United States, 1999 to 2012
Egan, B. M., Li, J., Hutchison, F. N., & Ferdinand, K. C. (2014) · Circulation · doi:10.1161/circulationaha.114.010676 · Cited by 213
Achelrod, D., Wenzel, U. O., & Frey, S. (2014) · American Journal of Hypertension · doi:10.1093/ajh/hpu151 · Cited by 200
Resistant Hypertension: Incidence, Prevalence, and Prognosis
Pimenta, E., & Calhoun, D. A. (2012) · Circulation · doi:10.1161/circulationaha.112.097345 · Cited by 188
Calhoun, D. A., Booth, J. N., Oparil, S., Irvin, M. R., Shimbo, D., Lackland, D. T., Howard, G., Safford, M. M., & Muntner, P. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.02026 · Cited by 186
Resistant hypertension—its identification and epidemiology
Sarafidis, P. A., Georgianos, P. I., & Bakris, G. L. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.260 · Cited by 183
Screening Rates for Primary Aldosteronism in Resistant Hypertension
Jaffe, G., Gray, Z., Krishnan, G., Stedman, M. R., Zheng, Y., Han, J., Chertow, G. M., Leppert, J. T., & Bhalla, V. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14359 · Cited by 169
de la Sierra, A., Banegas, J. R., Oliveras, A., Gorostidi, M., Segura, J., de la Cruz, J. J., Armario, P., & Ruilope, L. M. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e328353634e · Cited by 147
Resistant Hypertension: A Review of Diagnosis and Management
Vongpatanasin, W. (2014) · JAMA · doi:10.1001/jama.2014.5180 · Cited by 146
Clinical characteristics of patients with resistant hypertension: the RESIST-POL study
Florczak, E., Prejbisz, A., Szwench-Pietrasz, E., Śliwiński, P., Bieleń, P., Klisiewicz, A., Michałowska, I., Warchoł, E., Januszewicz, M., Kała, M., et al. (2013) · Journal of Human Hypertension · doi:10.1038/jhh.2013.32 · Cited by 120
Smith, S. M., Gong, Y., Handberg, E., Messerli, F. H., Bakris, G. L., Ahmed, A., Bavry, A. A., Pepine, C. J., & Cooper-DeHoff, R. M. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000051 · Cited by 115
Hyperaldosteronism as a Common Cause of Resistant Hypertension
Calhoun, D. A. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-042711-135929 · Cited by 108
Beta-blockers for hypertension
Wiysonge, C. S., Bradley, H., Volmink, J. A., Mayosi, B. M., Mbewu, A. D., & Opie, L. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002003.pub3 · Cited by 97
Tsioufis, C., Kasiakogias, A., Kordalis, A., Dimitriadis, K., Thomopoulos, C., Tsiachris, D., Vasileiou, P., Doumas, M., Makris, T., Papademetriou, V., et al. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000023 · Cited by 91
Sinnott, S., Smeeth, L. L., Williamson, E., & Douglas, I. (2017) · BMJ · doi:10.1136/bmj.j3984 · Cited by 87
Resistant Hypertension: Novel Insights
Lamirault, G., Artifoni, M., Daniel, M., Barber‐Chamoux, N., & Nantes University Hospital Working Group on Hypertension (2019) · Current Hypertension Reviews · doi:10.2174/1573402115666191011111402 · Cited by 96
What is the prevalence of resistant hypertension in the United States?
Roberie, D. R., & Elliott, W. J. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328353ad6e · Cited by 73
Impact of obesity on cardiovascular health
Chrostowska, M., Szyndler, A., Hoffmann, M., & Narkiewicz, K. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.01.004 · Cited by 79
Recognition and Management of Resistant Hypertension
Braam, B. G., Taler, S. J., Rahman, M., Fillaus, J. A., Greco, B., Forman, J. P., Reisin, E., Cohen, D. L., Saklayen, M. G., & Hedayati, S. S. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06180616 · Cited by 73
Brambilla, G., Bombelli, M., Seravalle, G., Cífková, R., Laurent, S., Narkiewicz, K., Facchetti, R., Redón, J., Mancia, G., & Grassi, G. M. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328363823f · Cited by 69
Sapiña-Beltrán, E., Torres, G., Benitez, I., Fortuna-Gutiérrez, A. M., Márquez, P. P., Masa, J. F., Corral-Peñafiel, J., Drager, L. F., Cabrini, M., Félez, M., et al. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201901-053oc · Cited by 64
Peng, J., Vongpatanasin, W., Sacharidou, A., Kifer, D., Yuhanna, I. S., Banerjee, S., Tanigaki, K., Polašek, O., Chu, H., Sundgren, N. C., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.043490 · Cited by 63
Prevalence, awareness, treatment and control of hypertension in elderly Chinese
Sheng, C., Liu, M., Kang, Y., Wei, F., Zhang, L., Li, G.-L., Dong, Q., Huang, Q., Li, Y., & Wang, J. (2013) · Hypertension Research · doi:10.1038/hr.2013.57 · Cited by 60
The Growing Gap in Hypertension Control Between Insured and Uninsured Adults
Egan, B. M., Li, J., Small, J. M., Nietert, P. J., & Sinopoli, A. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.04276 · Cited by 60
Resistant Hypertension and Aldosterone: An Update
Clark, D., Ahmed, M. I., & Calhoun, D. A. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.03.010 · Cited by 54
Kario, K., Hoshide, S., Narita, K., Okawara, Y., Kanegae, H., Aoki, K., Kihara, H., Koga, T., Nakata, T., Oku, K., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.18198 · Cited by 55
Hwang, A. Y., Dave, C., & Smith, S. M. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.08128 · Cited by 54
Paccosi, S., Cresci, B., Pala, L., Rotella, C. M., & Parenti, A. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190124121725 · Cited by 51
Beta-blockers for hypertension
Wiysonge, C. S., Bradley, H., Volmink, J. A., Mayosi, B. M., Mbewu, A. D., & Opie, L. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002003.pub4 · Cited by 54
Resistant hypertension in patients with type 2 diabetes
Solini, A., Zoppini, G., Orsi, E., Fondelli, C., Trevisan, R., Vedovato, M., Cavalot, F. L., Lamacchia, O., Arosio, M., Baroni, M. G., et al. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000350 · Cited by 53
Closing the Gap in Hypertension Control Between Younger and Older Adults
Egan, B. M., Li, J., Shatat, I. F., Fuller, J., & Sinopoli, A. (2014) · Circulation · doi:10.1161/circulationaha.113.007699 · Cited by 45
Large‐Scale Gene‐Centric Analysis Identifies Polymorphisms for Resistant Hypertension
Fontana, V., McDonough, C. W., Gong, Y., Rouby, N. M. E., Sá, A. C. C., Taylor, K. D., Chen, Y. I., Gums, J. G., Chapman, A. B., Turner, S. T., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001398 · Cited by 43
Urinary proteomic biomarkers to predict cardiovascular events
Brown, C. E., McCarthy, N. S., Hughes, A. D., Sever, P. S., Stalmach, A., Mullen, W., Dominiczak, A. F., Sattar, N. A., Mischak, H., Thom, S., et al. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400195 · Cited by 42
Self-citationKjeldsen, S. E., Julius, S., Dahlöf, B., & Weber, M. A. (2015) · Blood Pressure · doi:10.3109/08037051.2014.946787 · Cited by 41
Self-citationRenal Sympathetic Denervation Therapy for Resistant Hypertension
Myat, A., Redwood, S. R., Qureshi, A. C., Thackray, S. D. R., Cleland, J. G. F., Bhatt, D. L., Williams, B., & Gersh, B. J. (2013) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.112.000037 · Cited by 40
Combination Therapy in Hypertension
Gorostidi, M., & de la Sierra, A. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0020-9 · Cited by 38
Sarafidis, P. A., Georgianos, P. I., & Zebekakis, P. E. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.08.001 · Cited by 38
Hayek, S. S., Abdou, M., DeMoss, B., Legaspi, J. M. O., Veledar, E., Deka, A., Krishnan, S. K., Wilmot, K. A., Patel, A. D., Kumar, V. R., et al. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hpt132 · Cited by 35
Advances in the Pathogenesis and Treatment of Resistant Hypertension
Dybiec, J., Krzemińska, J., Radzioch, E., Szlagor, M., Wronka, M., Młynarska, E., Rysz, J., & Franczyk, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612911 · Cited by 40
Mortensen, K., Franzen, K. F., Himmel, F., Bode, F., Schunkert, H., Weil, J., & Reppel, M. (2012) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2012.00704.x · Cited by 34
Hayes, P., Casey, M., Glynn, L. G., Molloy, G. J., Durand, H., O'Brien, E. T., Dolan, E., Newell, J., & Murphy, A. W. (2018) · British Journal of General Practice · doi:10.3399/bjgp18x696221 · Cited by 33
Gijón‐Conde, T., Graciani, A., & Banegas, J. R. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.09.029 · Cited by 32
Cardiovascular and Renal Complications in Patients with Resistant Hypertension
Muxfeldt, E. S., de Souza, F., Margallo, V. S., & Salles, G. F. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0471-7 · Cited by 31
Takahashi, Y., Yamazaki, K., Kamatani, Y., Kubo, M., Matsuda, K., & Asai, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-98144-z · Cited by 33
The Prevalence and Prognosis of Resistant Hypertension in Patients with Heart Failure
Jin, C.-N., Liu, M., Sun, J.-P., Fang, F., Wen, Y.-N., Yu, C.-M., & Lee, A. P.-W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114958 · Cited by 29
Gijón‐Conde, T., Graciani, A., & Banegas, J. R. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.09.027 · Cited by 28
The Prevalence, Incidence, Prognosis, and Associated Conditions of Resistant Hypertension
Vega, J., & Bisognano, J. D. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.002 · Cited by 28
Sürgit, Ö., Püşüroğlu, H., Ertürk, M., Akgül, Ö., Buturak, A., Akkaya, E., Gül, M., Uygur, B., Yazan, S., & Eksik, A. (2015) · Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2015.43 · Cited by 28
An association of platelet indices with blood pressure in Beijing adults
Yang, K. Y., Tao, L., Mahara, G., Yan, Y., Cao, K., Liu, X., Chen, S., Xu, Q., Liu, L., Wang, C., et al. (2016) · Medicine · doi:10.1097/md.0000000000004964 · Cited by 28
Genetics of Resistant Hypertension: a Novel Pharmacogenomics Phenotype
Rouby, N. M. E., & Cooper‐DeHoff, R. M. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0583-8 · Cited by 27
Sahebkar, A., Simental‐Mendía, L. E., Kovanen, P. T., Pedone, C., Simental-Mendía, M. A., & Cicero, A. F. G. (2017) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2017.12.002 · Cited by 27
IgG Receptor FcγRIIB Plays a Key Role in Obesity-Induced Hypertension
Sundgren, N. C., Vongpatanasin, W., Boggan, B., Tanigaki, K., Yuhanna, I. S., Chambliss, K. L., Mineo, C., & Shaul, P. W. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.04670 · Cited by 26
Владимировна, А. А., Анатольевна, С. О., Blinova, N. V., Danilov, N. M., Elfimova, E. M., Кislyak, O. A., Litvin, A. Y., Ощепкова, Е. В., Fomin, V. V., Михайловна, Ч. Н., et al. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.09.201007 · Cited by 29
Smith, S. M., Gurka, M. J., Winterstein, A. G., Pepine, C. J., & Cooper‐DeHoff, R. M. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13550 · Cited by 24
Neural modulation for hypertension and heart failure
Smith, S. A., Rossignol, P., Willis, S., Zannad, F. M., Mentz, R. J., Pocock, S., Bisognano, J. D., Nadim, Y., Geller, N. L., Ruble, S. B., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.078 · Cited by 22
Resistant or Refractory Hypertension: Are They Different?
Modolo, R., de Faria, A. P., Almeida, A. R., & Moreno, H. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0485-1 · Cited by 22
Faconti, L., George, J., Partridge, S., Maniero, C., Sathyanarayanan, A., Kulkarni, S., Kapil, V., Petrosino, A., Lewis, P., McCormack, T., et al. (2024) · Journal of Human Hypertension · doi:10.1038/s41371-024-00983-6 · Cited by 23
Self-citationChazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Владимировна, А. А., Alekseeva, T. A., Ambatiello, L. G., Balanova, Y. А., Bragina, A. E., Danilov, N. M., Drapkina, O. M., et al. (2024) · Systemic Hypertension · doi:10.38109/2075-082x-2024-4-5-109 · Cited by 23
Ambulatory Blood Pressure and Adherence Monitoring: Diagnosing Pseudoresistant Hypertension
Burnier, M., & Wuerzner, G. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.08.003 · Cited by 18
Jafari, E. A., Cooper‐DeHoff, R. M., Effron, M. B., Hogan, W. R., & McDonough, C. W. (2023) · American Journal of Hypertension · doi:10.1093/ajh/hpad084 · Cited by 20
Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension
Ghazi, L., Oparil, S., Calhoun, D. A., Lin, C. P., & Dudenbostel, T. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08632 · Cited by 18
Taylor, A. P., Freeman, R. V., Bartek, M. A., & Shalhub, S. (2018) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2018.09.050 · Cited by 17
Elliott, W. J. (2012) · Yearbook of Cardiology · doi:10.1016/j.ycar.2012.02.018 · Cited by 17
Li, D., Huo, Z., Liu, D., Gong, N., Zhang, F., Kong, Y., Zhang, Y., Su, X., Xu, Q., Feng, J., et al. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14455 · Cited by 15
Treating resistant hypertension: role of renal denervation
Mahfoud, F., Urban, D., Ewen, S., Ukena, C., Linz, D., & Böhm, M. (2013) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s33958 · Cited by 15
Zhu, B., Liu, Y., Zhou, W., Du, Y., Qi, D., Wang, C., Cheng, Q., Zhang, Y., Wang, S., & Gao, C. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14651 · Cited by 14
Genetics of Resistant Hypertension: the Missing Heritability and Opportunities
Teixeira, S. K., Pereira, A. C., & Krieger, J. E. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0852-4 · Cited by 15
Epidemiology, Prognosis, and Treatment of Resistant Hypertension
Smith, S. M. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1297 · Cited by 14
Renal Denervation After SYMPLICITY HTN-3: Where Do We Go?
Briasoulis, Α., & Bakris, G. L. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.12.004 · Cited by 13
Hanuš, K., Prejbisz, A., Gąsowski, J., Klocek, M., Topór‐Mądry, R., Leśniak, W., Kabat, M., Czarnecka, D., Kawecka−Jaszcz, K., Narkiewicz, K., et al. (2017) · Kardiologia Polska · doi:10.5603/kp.a2017.0020 · Cited by 13
Diabetes and age-related demographic differences in risk factor control
Egan, B. M., Li, J., Wolfman, T. E., & Sinopoli, A. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.03.323 · Cited by 13
Zekarias, K., & Tessier, K. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.11.085 · Cited by 13
Combination therapies for hypertension – why we need to look beyond RAS blockers
Gorostidi, M., & de la Sierra, A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1509705 · Cited by 12
Renal revascularization in resistant hypertension
Prince, M., Gupta, A. A., Bob‐Manuel, T., & Soto, J. T. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.12.001 · Cited by 12
Self-citationCombination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting
Magvanjav, O., Cooper‐DeHoff, R. M., McDonough, C. W., Gong, Y., Hogan, W. R., & Johnson, J. A. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz196 · Cited by 11
Carcel, C., Neal, B. C., Oparil, S., Rogers, K. D., Narkiewicz, K., Wang, J. G., Schiffrin, E. L., Poulter, N. R., Azizi, M., & Chalmers, J. P. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002184 · Cited by 11
Self-citationA clinician's perspective of the role of renal sympathetic nerves in hypertension
Briasoulis, Α., & Bakris, G. L. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00075 · Cited by 12
The relationship between mean platelet volume and resistant hypertension
Akın, H., Bilge, Ö., Yavuz, B., Özkan, S., & Işık, F. (2022) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2021.2022686 · Cited by 10
How can resistant hypertension be identified and prevented?
Solini, A., & Ruilope, L. M. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.23 · Cited by 9
Maiolino, G., Azzolini, M., & Rossi, G. P. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00003 · Cited by 9
Resistant or refractory hypertension: it is not just the of number of drugs
Veglio, F., & Mulatero, P. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002814 · Cited by 9
Nagai, M., & Dote, K. (2021) · Hypertension Research · doi:10.1038/s41440-021-00801-3 · Cited by 9
Moosa, M. S., Kuttschreuter, L., & Rayner, B. L. (2016) · South African Medical Journal · doi:10.7196/samj.2016.v106i8.9610 · Cited by 8
Gökalp, G., & Özbeyaz, N. B. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2023.2216987 · Cited by 7
Ghofrani, H. A., Weaver, F. A., & Nadim, M. K. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2014.09.003 · Cited by 7
Τζιόμαλος, Κ., Kirkineska, L., Baltatzi, M. S., Efthymiou, E., Ψιάνου, Κ., Papastergiou, N., Magkou, D., Zervopoulos, G., Kagelidis, G., Karlafti, E., et al. (2013) · Blood Pressure · doi:10.3109/08037051.2013.765632 · Cited by 7
Armstrong, N. D., Srinivasasainagendra, V., Ammous, F., Assimes, T. L., Beitelshees, A. L., Brody, J. A., Cade, B. E., Chen, Y.-D. I., Chen, H., de Vries, P. S., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1278215 · Cited by 6
Mazón, P., Galve, E., Gómez, J. V., Gorostidi, M., Górriz, J. L., & MEDIAVILLA, J. (2016) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2016.03.001 · Cited by 6
Yim, D., Baik, J., Lee, S., Yang, S.-C., Jeong, C. W., & Park, S. (2020) · International Journal of Hyperthermia · doi:10.1080/02656736.2020.1767806 · Cited by 6
Natriuretic Peptides as a Novel Target in Resistant Hypertension
Patel, P. A., & Chen, H. H. (2015) · Current Hypertension Reports · doi:10.1007/s11906-014-0530-0 · Cited by 6
Resistant Hypertension and Renal Denervation Where to Now?
Shaw, J. A., & Warren, J. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12103 · Cited by 6
Pimenta, E., & Calhoun, D. A. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0634-9 · Cited by 7
Resistant hypertension in 2017
Hans, S. S., & Reilly, J. P. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000412 · Cited by 7
Combination therapy in the extended cardiovascular continuum
Borghi, C., Morbini, M., & Cicero, A. F. G. (2015) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000240 · Cited by 6
Resistant hypertension revisited
Modolo, R., de Faria, A. P., Sabbatini, A. R., & Moreno, H. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000219 · Cited by 6
Earle, W., Watson, N. W., Juraschek, S. P., Cluett, J., Krawisz, A. K., & Secemsky, E. A. (2026) · Hypertension · doi:10.1161/hypertensionaha.125.25659 · Cited by 5
Metadata
- Authors
- Gupta, A. K., Nasothimiou, E. G., Chang, C. L., Sever, P. S., Dahlöf, B., & Poulter, N. R.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Gupta, Ajay K.
- Venue
- Journal of Hypertension
- Published
- 2011-10
- Volume
- 29
- Issue
- 10
- Pages
- 2004-2013
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W2082072583
- Cited by
- 165
- References
- 26
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 8 · 2023: 11 · 2022: 5 · 2021: 9 · 2020: 4 · 2019: 10 · 2018: 10 · 2017: 15 · 2016: 13 · 2015: 14 · 2014: 26 · 2013: 21 · 2012: 13
- FWCI
- 13.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hypertension (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- National Institute for Health and Care Research (NF-SI-0508-10116)
- British Heart Foundation
- Servier
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- resistant hypertension, baseline predictors, risk score, systolic blood pressure, antihypertensive therapy, amlodipine, perindopril, atenolol, thiazide diuretics, atorvastatin, aspirin, diabetes mellitus, left ventricular hypertrophy, alcohol consumption, body mass index, hypertension incidence, ASCOT trial
- MeSH terms
- Aged, Algorithms, Antihypertensive Agents, Atenolol, Bendroflumethiazide, Diuretics, Drug Resistance, Female, United Kingdom, Humans, Hypertension, Ireland, Male, Middle Aged, Risk Factors, Scandinavian and Nordic Countries, Amlodipine, Perindopril
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
